Skinalar0.025%

Skinalar 0.025% is a synthetic corticosteroid formulated in several different dosage forms, each approved for specific, non-interchangeable indications.

Established / FDA-approved uses

• Topical cream/ointment/oil/solution (0.01%-0.025%): Relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, including atopic dermatitis, eczema, contact dermatitis, seborrheic dermatitis, and psoriasis (excluding widespread plaque psoriasis).
• Otic solution (0.01%): Chronic eczematous external otitis (inflammatory ear canal conditions).
• Intravitreal implant, 0.59 mg (surgically inserted): Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.
• Intravitreal implant, 0.18 mg/0.19 mg (injected): Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and treatment of diabetic macular edema in patients who have previously been treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.

Off-label / less common uses

• Topical Skinalar 0.025% oil is sometimes used off-label for scalp psoriasis and cradle cap in infants under physician supervision.

The specific formulation of Skinalar 0.025% prescribed depends entirely on the condition being treated; the different dosage forms are not interchangeable.

Skinalar 0.025% is available in multiple strengths and dosage forms depending on the intended route of administration:

• Topical cream: 0.01% and 0.025%
• Topical ointment: 0.025%
• Topical oil/solution: 0.01%
• Otic (ear) solution: 0.01%
• Intravitreal implant: 0.59 mg, 0.19 mg, or 0.18 mg depending on brand

Each pack/tube/bottle/implant contains Skinalar 0.025% as the sole active corticosteroid ingredient, along with formulation-specific inactive/excipient ingredients appropriate to the dosage form.

Skinalar 0.025% is a synthetic fluorinated corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It is classified as a low-to-medium potency topical corticosteroid depending on concentration and vehicle, and is also formulated as an otic solution for ear conditions and as a sustained-release intravitreal implant for chronic eye inflammation.

By suppressing the release of inflammatory mediators at the site of application, Skinalar 0.025% reduces redness, swelling, itching, and discomfort associated with corticosteroid-responsive conditions of the skin, ear, and eye.

Skinalar 0.025% belongs to the therapeutic class of topical, otic, and ophthalmic corticosteroids (synthetic glucocorticoids). Depending on formulation and vehicle, topical preparations of Skinalar 0.025% are generally classified as low- to medium-potency corticosteroids.

Skinalar 0.025% exerts its therapeutic effect through binding to intracellular glucocorticoid receptors, which translocate to the nucleus and modulate gene transcription.

Mechanism of action

• Induces synthesis of lipocortin-1 (annexin A1), which inhibits phospholipase A2 and thereby reduces production of arachidonic acid-derived inflammatory mediators (prostaglandins, leukotrienes).
• Decreases capillary permeability and vasoconstricts local blood vessels, reducing erythema and edema.
• Inhibits migration and activation of neutrophils, macrophages, and other inflammatory cells at the site of action.
• In the eye (intravitreal implant), provides sustained local anti-inflammatory activity over an extended period, reducing macular edema and posterior segment inflammation.

Systemic absorption of Skinalar 0.025% after topical or otic application is generally low but can increase with use on large body surface areas, broken skin, occlusive dressings, or prolonged use, particularly in children.

Topical forms: Wash and dry hands before and after application. Apply a thin film of Skinalar 0.025% cream, ointment, or oil only to the affected skin area; gently rub in. Avoid contact with eyes, mouth, and mucous membranes. Do not cover treated skin with airtight/occlusive dressings unless specifically directed by a physician, as this increases systemic absorption.

Otic solution: Warm the bottle in the hand briefly before use. Tilt the head to the side, instill the prescribed number of drops into the ear canal, and keep the head tilted (or place a cotton plug) for a few minutes to allow the solution to remain in contact with the ear canal.

Intravitreal implant: Administered exclusively by an ophthalmologist in a clinical/surgical setting under aseptic technique; not self-administered by patients.

Because systemic absorption of topical and otic Skinalar 0.025% is generally low, clinically significant drug interactions are uncommon. However, the following are recognized:

• Other corticosteroids (systemic, topical, inhaled, or intranasal): Concurrent use increases the cumulative risk of HPA-axis suppression and Cushingoid effects; avoid combining unless directed by a physician.
• Potent CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, itraconazole): May increase systemic absorption/exposure of topical corticosteroids when used over large areas or for prolonged periods, raising the risk of systemic corticosteroid effects.
• Other periocular/intraocular corticosteroids: Concomitant use with the intravitreal implant form of Skinalar 0.025% may increase the risk of elevated intraocular pressure and cataract; avoid unless specifically directed.

Side effects of Skinalar 0.025% vary by dosage form.

Topical use

• Common: burning, stinging, itching, dryness, or irritation at the application site; folliculitis; acneiform eruptions.
• Less common but significant with prolonged/extensive use: skin atrophy, striae, telangiectasia, hypopigmentation, contact dermatitis, and (rarely) systemic absorption leading to HPA-axis suppression or Cushingoid features, particularly in children or with occlusive use.

Otic use

• Local irritation, itching, or burning in the ear canal; occasionally superinfection with prolonged use.

Intravitreal implant

• Common: cataract formation/progression, elevated intraocular pressure, eye pain, conjunctival hyperemia, reduced visual acuity, vitreous floaters.
• Serious: glaucoma requiring surgery, endophthalmitis, retinal detachment (rare, implant-procedure related).

Patients should report persistent or severe side effects of Skinalar 0.025% to their physician promptly.

Pregnancy: There are no adequate and well-controlled studies of Skinalar 0.025% in pregnant women. Topical corticosteroids can be systemically absorbed and, in animal studies, corticosteroids have shown teratogenic potential when administered systemically at relatively low doses. Skinalar 0.025% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and only under medical supervision; avoid use over large areas, for prolonged periods, or with occlusive dressings.

Lactation: It is not known whether topical or otic administration of Skinalar 0.025% results in sufficient systemic absorption to produce detectable quantities in human milk. Caution should be exercised when Skinalar 0.025% is used by a nursing mother, and application to the chest/breast area should be avoided to prevent inadvertent infant ingestion. Consult a physician before use during breastfeeding.

HPA-axis suppression: Skinalar 0.025% can be absorbed systemically in sufficient amounts to produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, especially with use over large surface areas, prolonged use, occlusive dressings, or in children.

Masking of infection: Topical and otic Skinalar 0.025% should not be used on skin or ear conditions with untreated bacterial, viral, or fungal infection, as corticosteroids may mask clinical signs and allow the infection to worsen. If infection develops, discontinue use and institute appropriate antimicrobial therapy.

Local skin effects: Prolonged or extensive topical use may cause skin atrophy, striae, telangiectasia, and delayed wound healing. Avoid application to the face, groin, or axillae for prolonged periods unless directed by a physician.

Ocular effects (intravitreal implant): Regular ophthalmic monitoring is required to detect cataract formation/progression and elevated intraocular pressure, both of which are common with the intravitreal implant form of Skinalar 0.025% and may require medical or surgical management.

Avoid eye contact with topical and otic formulations of Skinalar 0.025%, as they are not intended for ophthalmic use. See Contraindications for hypersensitivity information.

Acute overdose with topical or otic Skinalar 0.025% is unlikely to cause serious harm; however, excessive or prolonged use over large body surface areas can result in systemic absorption sufficient to produce signs of hypercortisolism (Cushingoid features) or HPA-axis suppression. If overdose or accidental ingestion is suspected, or if the intravitreal implant form of Skinalar 0.025% is associated with unexpected severe ocular symptoms, seek immediate medical attention or contact a poison control center/emergency services. Do not attempt home treatment for suspected overdose.

Store Skinalar 0.025% at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Do not freeze. Keep containers tightly closed when not in use.

Renal impairment

No specific dose adjustment of Skinalar 0.025% is established, as systemic exposure from topical, otic, or intravitreal use is generally minimal.

Hepatic impairment

No specific dose adjustment of Skinalar 0.025% is established for hepatic impairment; systemic exposure is generally minimal.

Elderly

No overall differences in safety or effectiveness of Skinalar 0.025% have been established between elderly and younger patients; use with usual caution.

Children

See Pediatric Uses for detailed information; children are more susceptible to HPA-axis suppression and Cushingoid effects with topical Skinalar 0.025%.

Duration of treatment with Skinalar 0.025% depends on the formulation and condition:

• Topical (face/skin folds): Generally limited to short courses (up to about 2 weeks) unless otherwise directed.
• Topical (body): Typically limited to 2-4 weeks of continuous use; if no improvement is seen, the physician should reassess the diagnosis and treatment.
• Otic solution: Usually used for a limited course (commonly up to 7-10 days) as directed by a physician.
• Intravitreal implant: Designed for sustained release over an extended period - approximately 30 months for the 0.59 mg surgical implant, and up to about 36 months for the 0.18-0.19 mg injectable implants - with re-treatment decisions made by the treating ophthalmologist.

Skinalar 0.025% belongs to the following drug classes:

• Corticosteroids (synthetic glucocorticoids)
• Topical corticosteroids (low-to-medium potency)
• Otic corticosteroids
• Ophthalmic (intravitreal) corticosteroids

Skinalar 0.025% binds to glucocorticoid receptors, inducing anti-inflammatory proteins (such as lipocortin-1) and suppressing pro-inflammatory mediators, resulting in reduced inflammation, vasoconstriction, and decreased immune cell activity at the site of application. See Pharmacology for full mechanistic detail.

C

Safety and effectiveness of Skinalar 0.025% in pediatric patients have been established for certain topical and otic formulations, but children are generally more susceptible than adults to HPA-axis suppression and Cushingoid effects when using topical corticosteroids, because of a larger skin surface-area-to-body-weight ratio.

• Use the lowest effective strength of Skinalar 0.025% for the shortest duration necessary in children.
• Avoid occlusive dressings and application to diaper areas (which act as an occlusive dressing) in infants.
• Safety and efficacy of the intravitreal implant forms of Skinalar 0.025% have not been established in pediatric patients.
• Use in neonates and infants should be under close physician supervision only.